MCID: SML001
MIFTS: 46

Small Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Mental diseases, Rare diseases, Respiratory diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Small Cell Carcinoma

MalaCards integrated aliases for Small Cell Carcinoma:

Name: Small Cell Carcinoma 11 14 16
Small Cell Carcinoma, Intermediate Cell 11 71
Small Cell Carcinoma - Intermediate Cell 11
Intermediate Cell Small Cell Carcinoma 11
Small Cell Carcinoma of Lung 71
Carcinoma, Small Cell 71
Small-Cell Carcinoma 75

Classifications:



External Ids:

Disease Ontology 11 DOID:0050685
NCIt 49 C4099
SNOMED-CT 68 5958006
UMLS 71 C0149925 C0262584 C0334239

Summaries for Small Cell Carcinoma

Disease Ontology: 11 A carcinoma that is an undifferentiated neoplasm composed of primitive-appearing cells.

MalaCards based summary: Small Cell Carcinoma, also known as small cell carcinoma, intermediate cell, is related to ovarian small cell carcinoma and bladder small cell carcinoma. An important gene associated with Small Cell Carcinoma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Neuroscience and Clear cell renal cell carcinoma pathways. The drugs BCG vaccine and Atezolizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, cervix and prostate, and related phenotypes are Decreased viability in pancreas lineage and nervous system

Wikipedia: 75 Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung,... more...

Related Diseases for Small Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 878)
# Related Disease Score Top Affiliating Genes
1 ovarian small cell carcinoma 33.1 SYP ENO2 CHGA
2 bladder small cell carcinoma 33.1 SYP NCAM1 ENO2
3 prostate small cell carcinoma 32.8 SYP ENO2
4 endometrial small cell carcinoma 32.7 SYP NCAM1 ENO2 CHGA
5 thymus small cell carcinoma 32.6 SYP ENO2 CHGA
6 cervix small cell carcinoma 32.6 SYP NCAM1 ENO2 CHGA
7 gastric small cell carcinoma 32.5 SYP NCAM1 ENO2 CHGA
8 laryngeal small cell carcinoma 32.5 SYP NKX2-1 NCAM1 CHGA
9 gallbladder small cell carcinoma 32.2 SYP NCAM1 ENO2 CHGA
10 small cell cancer of the lung 32.2 SYP PTEN NKX2-1 NCAM1 MYCN KRT7
11 ureter small cell carcinoma 32.1 SYP NKX2-1 NCAM1 KRT7 ENO2 CHGA
12 merkel cell carcinoma 31.5 SYP NKX2-1 NCAM1 KRT7 ENO2 CHGA
13 lung large cell carcinoma 31.4 SYP NKX2-1 NCAM1 KRT7 ENO2 CHGA
14 prostate cancer 31.3 XAGE1B XAGE1A PTEN PDPK1 MSR1 HOXB13
15 carcinoid tumors, intestinal 31.2 SYP NKX2-1 ENO2 CHGA
16 lung oat cell carcinoma 31.2 SYP PTEN ENO2 CHGA
17 carcinoid syndrome 31.1 SYP ENO2 CHGA
18 gallbladder adenocarcinoma 31.1 SYP KRT7 CHGA
19 neuroendocrine tumor 31.0 SYP NKX2-1 NCAM1 ENO2 CHGA
20 neuroendocrine carcinoma 30.9 SYP PTEN NKX2-1 NCAM1 KRT7 ENO2
21 suppression of tumorigenicity 12 30.8 SYP PTEN MYCN ENO2 CHGA
22 large cell carcinoma 30.7 SYP NKX2-1 KRT7 ENO2 CHGA
23 diffuse gastric cancer 30.7 PTEN MSR1 CHEK2
24 carcinosarcoma 30.6 SYP PTEN KRT7
25 adenosquamous carcinoma 30.6 NKX2-1 KRT7 CHGA
26 large cell neuroendocrine carcinoma 30.6 SYP NKX2-1 NCAM1 KRT7 ENO2 CHGA
27 appendix adenocarcinoma 30.5 SYP KRT7 CHGA
28 serous cystadenocarcinoma 30.5 PTEN KRT7 HNF1B
29 rhabdomyosarcoma 2 30.5 SYP NCAM1 MYCN ENO2
30 thyroid gland medullary carcinoma 30.5 SYP NKX2-1 CHGA
31 adenoid cystic carcinoma 30.4 PTEN NCAM1 MYCN KRT7 CHEK2
32 lung benign neoplasm 30.4 SYP NKX2-1 NCAM1 KRT7 ENO2 CHGA
33 ewing sarcoma 30.4 SYP NCAM1 MYCN ENO2 CHGA
34 adrenal carcinoma 30.4 SYP ENO2 CHGA
35 teratoma 30.3 SYP PTEN NKX2-1 KRT7 ENO2 CHGA
36 pleomorphic carcinoma 30.3 NKX2-1 KRT7
37 mixed cell type cancer 30.3 SYP PTEN KRT7 ENO2 CHGA
38 breast ductal carcinoma 30.3 SYP PTEN KRT7 CHGA
39 trachea carcinoma 30.3 NKX2-1 KRT7
40 gastrointestinal stromal tumor 30.2 SYP PTEN NCAM1 ENO2 CHGA
41 islet cell tumor 30.2 SYP NCAM1 ENO2 CHGA
42 papillary carcinoma 30.2 NKX2-1 KRT7 CHGA
43 embryonal rhabdomyosarcoma 30.2 NCAM1 MYCN ENO2
44 thymic carcinoma 30.2 SYP NKX2-1 KRT7
45 pulmonary large cell neuroendocrine carcinoma 30.2 SYP NKX2-1 NCAM1 ENO2 CHGA
46 ectopic cushing syndrome 30.2 SYP CHGA
47 neuroblastoma 30.1 SYP PTEN NCAM1 MYCN ENO2 DDX1
48 horner's syndrome 30.1 SYP MYCN ENO2
49 tubular adenocarcinoma 30.1 SYP NCAM1 KRT7 ENO2 CHGA
50 lung combined large cell neuroendocrine carcinoma 30.1 SYP ENO2 CHGA

Graphical network of the top 20 diseases related to Small Cell Carcinoma:



Diseases related to Small Cell Carcinoma

Symptoms & Phenotypes for Small Cell Carcinoma

GenomeRNAi Phenotypes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in pancreas lineage GR00235-A 8.62 CHEK2 KRT7

MGI Mouse Phenotypes related to Small Cell Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.73 CHEK2 CHGA ENO2 HOXB13 MSR1 MYCN
2 mortality/aging MP:0010768 9.47 CHEK2 CHGA DDX1 ENO1 HNF1B HOXB13

Drugs & Therapeutics for Small Cell Carcinoma

Drugs for Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 226)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
BCG vaccine Approved, Investigational Phase 3
2
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
3
Picropodophyllin Approved, Investigational Phase 2, Phase 3 518-28-5, 477-47-4 10607 72435
4
Memantine Approved, Investigational Phase 3 41100-52-1, 19982-08-2 4054
5
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3 3680
7
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 3003 5743
8
Ichthammol Approved Phase 2, Phase 3 8029-68-3
9
Mecobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
10
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 15589840 44475014
11
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
12
Osimertinib Approved Phase 3 1421373-65-0 71496458
13
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
14
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
15
Etoposide Approved Phase 3 33419-42-0 36462
16
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 24892734 16212801 44176380
17
Camptothecin Experimental Phase 3 7689-03-4 24360
18
Belotecan Investigational Phase 3 256411-32-2 9824190
19
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
20
Lexatumumab Investigational Phase 3 845816-02-6
21 Vaccines Phase 3
22 Keratolytic Agents Phase 2, Phase 3
23 Dermatologic Agents Phase 2, Phase 3
24 Dopamine Agents Phase 3
25 Antiparkinson Agents Phase 3
26 Excitatory Amino Acid Antagonists Phase 3
27 Vitamin B12 Phase 2, Phase 3
28 Vitamin B 12 Phase 2, Phase 3
29 Antiemetics Phase 2, Phase 3
30 BB 1101 Phase 2, Phase 3
31 Gastrointestinal Agents Phase 2, Phase 3
32 Endothelial Growth Factors Phase 3
33 Immunoglobulins, Intravenous Phase 3
34
Etoposide phosphate Phase 3 16760419
35 Hematinics Phase 3
36
Epoetin Alfa Phase 3
37
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
38
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
39
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
40
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
41
Lenograstim Approved, Investigational Phase 2 135968-09-1
42
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
43
Somatostatin Approved, Investigational Phase 1, Phase 2 38916-34-6, 51110-01-1 53481605 16129706
44
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
45
Sargramostim Approved, Investigational Phase 2 123774-72-1
46
Trastuzumab Approved, Investigational Phase 1, Phase 2 180288-69-1
47
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
48
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
49
Infliximab Approved Phase 1, Phase 2 170277-31-3
50
Vedolizumab Approved Phase 1, Phase 2 943609-66-3

Interventional clinical trials:

(show top 50) (show all 338)
# Name Status NCT ID Phase Drugs
1 International Multi-center Open-label Randomized Clinical Trial of Efficacy, Safety and Pharmacokinetics of BCD-100 (JSC "BIOCAD", Russia) Monotherapy Compared to Docetaxel as Second-line Therapy of Patients With Advanced Inoperable or Metastatic Non-small Cell Lung Cancer Unknown status NCT03288870 Phase 2, Phase 3 BCD-100;Docetaxel
2 Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer Unknown status NCT02688036 Phase 3
3 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
4 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
5 A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer Completed NCT00826644 Phase 3 Belotecan;Etoposide;Cisplatin
6 The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
7 A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy Completed NCT00270166 Phase 3 epoetin alfa
8 Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Recruiting NCT04181060 Phase 3 Osimertinib
9 MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) Recruiting NCT04155034 Phase 3
10 Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO) Recruiting NCT04267848 Phase 3 Carboplatin;Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Pemetrexed Disodium
11 Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC Recruiting NCT04092283 Phase 3 Carboplatin;Cisplatin;Etoposide;Paclitaxel;Pemetrexed Disodium
12 A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer Recruiting NCT04929041 Phase 2, Phase 3 Carboplatin;Nab-paclitaxel;Paclitaxel;Pemetrexed
13 Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer Recruiting NCT04804644 Phase 3 Memantine Hydrochloride
14 A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study) Recruiting NCT05096663 Phase 2, Phase 3 Dexamethasone;Docetaxel;Gemcitabine;Nogapendekin Alfa;Pemetrexed
15 Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab Recruiting NCT03811002 Phase 2, Phase 3 Atezolizumab;Carboplatin;Cisplatin;Etoposide
16 EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis Recruiting NCT03793179 Phase 3 Carboplatin;Pemetrexed
17 Role of Radiotherapy to the Primary Lesion in Metastatic Non-small Cell Lung Cancer Patients After First Line Systemic Therapy Recruiting NCT04776083 Phase 3 first line systemic therapy
18 PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer Recruiting NCT03774732 Phase 3 Pembrolizumab;Chemotherapy
19 Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year Recruiting NCT04588246 Phase 3 Memantine
20 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC Recruiting NCT04214262 Phase 3 Atezolizumab
21 Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) Recruiting NCT03391869 Phase 3
22 Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial Recruiting NCT04402788 Phase 2, Phase 3 Atezolizumab
23 Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) Recruiting NCT05058651 Phase 2, Phase 3 Carboplatin;Cisplatin;Etoposide
24 Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT02193282 Phase 3 Erlotinib Hydrochloride
25 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers Active, not recruiting NCT02595944 Phase 3
26 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00324805 Phase 3 Cisplatin;Docetaxel;Gemcitabine Hydrochloride;Pemetrexed Disodium;Vinorelbine Tartrate
27 Qualitative Study on Experiences Related to Anorexia and the Effects of Anamorelin and Placebo in Advanced Non-Small-Cell Lung Cancer Patients With Anorexia-Cachexia: A Preliminary Study Active, not recruiting NCT03637816 Phase 2, Phase 3 Anamorelin Hydrochloride
28 REPLATINUM: A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer Active, not recruiting NCT05566041 Phase 3 RRx-001 + eLOOP Device;Cisplatin/carboplatin plus etoposide
29 Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer Not yet recruiting NCT05624996 Phase 3 Carboplatin;Cisplatin;Etoposide;Paclitaxel;Pemetrexed
30 Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations Not yet recruiting NCT04695925 Phase 3 Osimertinib 80 MG [Tagrisso];Pemetrexed 500 MG Injection;Carboplatin
31 Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer Not yet recruiting NCT05633602 Phase 3 Chemotherapy
32 Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20) Terminated NCT00310232 Phase 3 Epoetin Alfa
33 A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer Terminated NCT03699956 Phase 3 Cisplatin/carboplatin plus etoposide
34 A Randomized, Phase III Dose Response Study of Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Lung Withdrawn NCT00006344 Phase 3
35 The Effect Of Aspirin On Survival Following Potentially Curative Resection Of Non Small Cell Carcinoma Of The Lung The Big A Trial Withdrawn NCT01058902 Phase 3 Aspirin 75 mg
36 Prospective Phase II Trial of a Combination of Gemcitabine and UFT as First-Line Treatment in Elderly Patients With Advanced Non-Small Cell Carcinoma Unknown status NCT00625352 Phase 2 Gemcitabine, UFT
37 Phase I/II Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC) Unknown status NCT01027676 Phase 1, Phase 2 Study treatment
38 Phase II Study of Surgery Combined With Recombinant Adenoviral Human p53 Gene Therapy in Treatment Advanced Non-small-cell Carcinoma Unknown status NCT01574729 Phase 2 Surgery combined with rAd-p53 gene therapy
39 Phase II Clinical Trial of Toripalimab (JS001), a Recombinant Humanized Anti-PD-1 Monoclonal PD1 Antibody, as Monotherapy for Patients With Small Cell Esophageal Carcinoma Who Failed Chemotherapy Unknown status NCT03811379 Phase 2 Toripalimab
40 Phase Ⅱ Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer Unknown status NCT01635400 Phase 2 Irinotecan
41 Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer Unknown status NCT01900951 Phase 2 Temozolomide
42 Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study Completed NCT00453154 Phase 1, Phase 2 Carboplatin;Cisplatin;Etoposide;Sunitinib Malate
43 A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Patients With Non-small Cell Carcinoma of the Lung. (PEARL Trial) Completed NCT00391248 Phase 2 Erlotinib
44 A Pilot Phase II Protocol Of Arsenic Trioxide (Trisenox) In Subjects With Advanced Non-Small Cell Carcinoma Of The Lung Completed NCT00075426 Phase 2 arsenic trioxide
45 A Randomized Trial of Pivanex Plus Docetaxel or Docetaxel Monotherapy in Patients With Chemotherapy Resistant Advanced Non-Small Cell Carcinoma of the Lung (NSCLC) Completed NCT00073385 Phase 2 Pivanex;Docetaxel
46 Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma Completed NCT00212043 Phase 2 carboplatin and gemcitabine
47 LCCC 0215: Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim Support Followed by Conformal Radiotherapy and Paclitaxel/Carboplatin/ZD1839 in Locally Advanced Unresectable Stage IIIA/B Non-Small Cell Carcinoma of the Lung Completed NCT00280787 Phase 2 Paclitaxel;Carboplatin;CPT-11;Pegfilgrastim
48 A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) Completed NCT02489903 Phase 2 RRx-001;Cisplatin;Etoposide;Carboplatin;Irinotecan;Vinorelbine;Doxil;Gemcitabine;Taxane;Paclitaxel;Nab-Paclitaxel;Pemetrexed
49 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
50 Pilot Study to Evaluate the Effect of Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer Completed NCT03394105 Phase 2 intrapleural docetaxel administration

Search NIH Clinical Center for Small Cell Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cisplatin
CISPLATIN PWDR
Teniposide
Topotecan
Topotecan Hydrochloride

Genetic Tests for Small Cell Carcinoma

Anatomical Context for Small Cell Carcinoma

Organs/tissues related to Small Cell Carcinoma:

MalaCards : Lung, Cervix, Prostate, Lymph Node, Brain, Bone Marrow, Ovary

Publications for Small Cell Carcinoma

Articles related to Small Cell Carcinoma:

(show top 50) (show all 7281)
# Title Authors PMID Year
1
Small-Cell Carcinoma of Nasopharynx: A Case Report of Unusual Localization. 62
33371727 2023
2
Opium use and risk of lung cancer: A multicenter case-control study in Iran. 62
36043555 2023
3
Small-cell neuroendocrine carcinoma of the vagina: A case report. 62
36453163 2022
4
Influence of ABO blood group on susceptibility to different pathological types of lung cancer: a retrospective study. 62
36464709 2022
5
Surgical resection combined with perioperative chemotherapy for a patient with locally recurrent, previously stage IV thymic small-cell carcinoma: A case report. 62
36345130 2022
6
ASO Visual Abstract: Prognostic Factors and Survival in Gastrointestinal Extrapulmonary Small Cell Carcinoma-A Retrospective Cohort Study. 62
36036843 2022
7
ASO Author Reflections: Prognostic Factors in Gastrointestinal Extrapulmonary Small Cell Carcinoma Using Real-World Data. 62
36006493 2022
8
Limited-stage small cell carcinoma of the esophagus treated with curative esophagectomy: A multicenter retrospective cohort study. 62
36036894 2022
9
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): A review and novel case with dual germline SMARCA4 and BRCA2 mutations. 62
36249907 2022
10
Prognostic Factors and Survival in Gastrointestinal Extrapulmonary Small Cell Carcinoma: A Retrospective Cohort Study. 62
35978206 2022
11
Prostate cancer recurring as small-cell carcinoma with a BRCA2 somatic mutation. 62
36341199 2022
12
Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate. 62
35704939 2022
13
Leptomeningeal carcinomatosis in small cell carcinoma of the prostate. 62
36341201 2022
14
Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications. 62
35867808 2022
15
[Two Cases of TKI-resistant Small Cell Lung Cancer Transformation 
in Advanced Adenocarcinoma and Literature Review]. 62
36419397 2022
16
Small Cell and Other Rare Histologic Types of Cervical Cancer. 62
35947285 2022
17
NOL4 is a novel nuclear marker of small cell carcinoma and other neuroendocrine neoplasms. 62
36282054 2022
18
Small Biopsy and Cytology of Pulmonary Neuroendocrine Neoplasms: Brief Overview of Classification, Immunohistochemistry, Molecular Profiles, and World Health Organization Updates. 62
36053019 2022
19
[Clinical analysis of 12 cases of laryngeal neuroendocrine carcinoma]. 62
36404660 2022
20
Cutaneous metastases of non-cutaneous neuroendocrine neoplasms: A histopathologic review of 15 cases. 62
36222210 2022
21
RhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma. 62
36323745 2022
22
[Early onset of small cell carcinom of the lung in a young patient in Benin]. 62
36088182 2022
23
Cardiac metastasis from small cell lung cancer origin: A case report and review of the literature. 62
36117246 2022
24
Metastatic lung carcinoma in thyroid aspirates: A case series and literature review illustrating diagnostic challenges. 62
35808980 2022
25
Low-grade tracheal adenocarcinoma with ETV6::NTRK3 fusion: unique morphology akin to subsets of sinonasal low-grade non-intestinal-type adenocarcinoma. 62
35670854 2022
26
Patterns of Extrathoracic Metastasis in Lung Cancer Patients. 62
36421344 2022
27
Lung cancer incidence attributable to residential radon exposure in Finland. 62
36344858 2022
28
Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study. 62
36331674 2022
29
Immunosensitivity and specificity of insulinoma-associated protein 1 (INSM1) for neuroendocrine neoplasms of the uterine cervix. 62
36245222 2022
30
[Study on the relationship between the pathological type of lung cancer caused by coke oven discharge and the contact type and exposure time]. 62
36348558 2022
31
TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients. 62
36295566 2022
32
Small cell neuroendocrine carcinoma of vagina: Report of a unique case with literature review. 62
36274474 2022
33
Semi-Supervised Adversarial Learning for Improving the Diagnosis of Pulmonary Nodules. 62
36269913 2022
34
A case report of pulmonary combined small cell carcinoma with enteric adenocarcinoma. 62
36388049 2022
35
Metastatic prostate cancer diagnosed by fine needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates. 62
36264673 2022
36
Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma. 62
36244466 2022
37
Preoperative Chemotherapy for Limited-stage Small Cell Carcinoma of the Esophagus. 62
34610332 2022
38
Surgical treatment of intermediate to high grade thymic neuroendocrine neoplasms: case series of five patients and literature review. 62
36388024 2022
39
Atypical Carcinoid Syndrome in a Patient Presenting With Pericarditis and Supraventricular Tachycardia: A Case Report. 62
36381843 2022
40
Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis. 62
35964518 2022
41
Small Cell Carcinoma of Ovary, Hypercalcemic Type: A Rare Case Report. 62
36243275 2022
42
Lymphadenectomy Benefits Small Cell Carcinoma of Ovary: A Population-Based Analysis. 62
36290894 2022
43
Small Cell Carcinoma of the Vagina: First Systematic Review of Case Reports and Proposal of a Management Algorithm. 62
36282979 2022
44
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. 62
35676169 2022
45
Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy: A Case Report. 62
36130891 2022
46
Small-cell carcinoma of the gall bladder: Report of three cases and review of the literature. 62
36147409 2022
47
Umbilical metastasis as an initial presentation of gastrointestinal stromal tumour diagnosed on aspiration cytology. 62
35689547 2022
48
Diagnostic accuracy and adequacy of peripheral pulmonary nodules samples obtained by transthoracic needle aspiration. 62
36062401 2022
49
Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib. 62
35689552 2022
50
Clinical characteristics and treatment outcomes of patients with small cell carcinoma of the urinary bladder. 62
36204354 2022

Variations for Small Cell Carcinoma

Expression for Small Cell Carcinoma

Search GEO for disease gene expression data for Small Cell Carcinoma.

Pathways for Small Cell Carcinoma

Pathways related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 SYP NKX2-1 NCAM1 MYCN ENO2
2 11.26 PTEN ENO2 ENO1
3 11.14 SYP PTEN PDPK1 NCAM1 MYCN

GO Terms for Small Cell Carcinoma

Cellular components related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphopyruvate hydratase complex GO:0000015 8.92 ENO2 ENO1

Molecular functions related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphopyruvate hydratase activity GO:0004634 8.92 ENO2 ENO1

Sources for Small Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....